
What is claimed:

1. A compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a fused (4- to 8-membered)oxygen-containing heterocycloalkyl ring, a fused phenyl ring, or a fused (5- to 8-membered)nitrogen-containing heteroaryl ring, wherein, when chemically permissible, the fused (4- to 8-membered)oxygen-containing heterocycloalkyl ring, the fused phenyl ring or the fused (5- to 8-membered)nitrogen-containing heteroaryl ring is optionally substituted with one to six R^8, provided that when ring A is a fused phenyl ring, R^8 is not methoxy, nitro, halogen, or trifluoromethyl;

R^1 is (C_3-C_8)cycloalkyl, (4- to 10-membered)- heterocycloalkyl, (C_6-C_{10})aryl or (5- to 14-membered)heteroaryl, wherein, when chemically permissible, the (C_3-C_8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C_6-C_{10})aryl or (5- to 14-membered)heteroaryl is optionally substituted with one to six R^9;

R^2 is hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_1-C_{15})alkyl-OR^5, -C(=O)-R^5, -C(=O)-OR^5, -C(=O)-N(R^5)(R^6), -(SO_2)R^5, (C_3-C_8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C_6-C_{10})aryl or (5- to 14-membered)heteroaryl, wherein, when chemically permissible, the (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C_6-C_{10})aryl or (5- to 14-membered)heteroaryl is optionally substituted with one to six R^8, provided that when ring A is a fused phenyl ring, R^2 is not a (C_1-C_6)alkyl substituted with N(R^5)(R^6);

R^{3a}, where chemically permissible, is hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, $N(R^5)(R^6)$, optionally substituted (C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_1-C_6)alkoxy or optionally substituted (C_3-C_8)cycloalkyl; or

R^2 and R^{3a} taken together with the nitrogen and carbon atoms to which they are attached form a (4- to 6-membered)heterocycloalkyl ring, and where chemically permissible, the (4- to 6-membered)heterocycloalkyl ring is optionally substituted with one to six R^8;

when present, R^{3b} is hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, $N(R^5)(R^6)$, optionally substituted (C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_1-C_6)alkoxy or optionally substituted (C_3-C_8)cycloalkyl; or

R^{3a} and R^{3b} taken together with the carbon atom to which they are attached form a (C_3-C_6)cycloalkyl or (4- to 6-membered)heterocycloalkyl, and where chemically permissible, the (C_3-C_6)cycloalkyl or (4- to 6-membered)heterocycloalkyl are optionally substituted with one to six R^8.

R^{4a}, where chemically permissible, is selected from the group consisting of hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, $N(R^5)(R^6)$, optionally substituted (C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkyl and optionally substituted (C_1-C_6)alkoxy;

when present, R^{4b} is hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, $N(R^5)(R^6)$, optionally substituted (C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkyl and optionally substituted (C_1-C_6)alkoxy; or

R^{4a} and R^{4b} taken together with the carbon atom to which they are attached form a (C_3-C_6)cycloalkyl or (4- to 6-membered)heterocycloalkyl, and where chemically permissible, the (C_3-C_6)cycloalkyl or (4- to 6-membered)heterocycloalkyl is optionally substituted with one to sixR^8;

R^5 and R^6 at each occurrence are each independently selected from the group consisting of hydrogen and (C_1-C_6)alkyl;

R^7 is (C_1-C_6)alkyl;

when present, R^8 at each occurrence is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, $N(R^5)(R^6)$, optionally substituted

(C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkyl, and optionally substituted (C_1-C_6)alkoxy;

when present, R^9 at each occurrence is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_2-C_6)alkenyl, optionally substituted (C_2-C_6)alkynyl, optionally substituted (C_1-C_6)alkylthio, optionally substituted (C_1-C_6)alkoxy, -$N(R^5)(R^6)$, -$N(R^5)(C(O)R^6)$, -C(=O), -C(=O)-R^5, -C(=O)-OR^5, -$(SO_2)R^7$, and -$S(=O_2)N(R^5)(R^6)$;

------- is absent (forming a single bond) or a bond (forming a double bond); and

n is 0 or 1, provided when ------ is present to form a double bond then n is 0, and when ------ is absent to form a single bond n is 1.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein ring A is:

i) a fused (4- to 6-membered)oxygen-containing heterocycloalkyl ring selected from the group consisting of oxetanyl, dihydrofuranyl, tetrahydrofuranyl, and tetrahydropyranyl, each of which is optionally substituted with one to three R^8;

ii) a fused phenyl ring optionally substituted with one to three R^8, provided that R^8 is not methoxy, nitro, halogen, or trifluoromethyl; or

iii) a fused (5- to 6-membered)nitrogen-containing heteroaryl ring selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, thiazolyl, isothiazolyl, and pyrazolyl, each of which is optionally substituted with one to three R^8.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein ring A is a fused (4- to 6-membered)oxygen-containing heterocycloalkyl ring and the heterocycloalkyl ring is tetrahydropyranyl optionally substituted with one to three R^8.

4. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein ring A is a fused (5- to 6-membered)nitrogen-containing heteroaryl ring

selected from the group consisting of a pyridinyl ring, a pyrimidinyl ring, a pyrazinyl ring and a thiazolyl ring, each of which is optionally substituted with one to three R^8.

5. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein each R^8 is independently selected from the group consisting of halogen, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6), provided that when ring A is a fused phenyl ring:
a) ring A is not substituted with methoxy, nitro, halogen, or trifluoromethyl; and
b) R^2 is not a (C_1-C_6)alkyl substituted with N(R^5)(R^6).

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:

i) a (C_3-C_6)cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and cyclopentenyl, each of which is optionally substituted with one to three R^9;

ii) a substituted (4- to 10-membered)heterocycloalkyl selected from the group consisting of azetidinyl, dihydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydrotriazinyl, tetrahydropyrazolyl, tetrahydrooxazinyl, tetrahydropyrimidinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, octahydrobenzothiazolyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiazinyl, tetrahydrothiadiazinyl, tetrahydro-oxazolyl, morpholinyl, oxetanyl, tetrahydrodiazinyl, oxazinyl, oxathiazinyl, quinuclidinyl, chromanyl, isochromanyl, dihydrobenzodioxinyl, benzodioxolyl, benzoxazinyl, indolinyl, dihydrobenzofuranyl, tetrahydroquinolyl, isochromyl, dihydro-1*H*-isoindolyl, 2-azabicyclo[2.2.1]heptanonyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, 1,3-oxazolidin-3-yl, 1,4-oxazepan-1-yl, isothiazolidinyl, 1,3-

thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,2-tetrahydrothiazin-2-yl, 1,3-thiazinan-3-yl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, 1,4-oxazin-4-yl, oxazolidinonyl, 2-oxo-piperidinyl, each of which is optionally substituted with one to three R^9;

iii) a (C_6-C_{10})aryl selected from selected from phenyl or naphthyl, each of which is optionally substituted with one to three R^9; and

iv) a (5- to 14-membered)heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, imidazolyl, furanyl, isoxazolyl, isothiazolyl, 1,2,3-, 1,2,4, 1,2,5-, 1,3,4-oxadiazolyl, oxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrazolyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothienyl, benzoxadiazolyl, benzothiazolyl, isobenzothiofuranyl, benzothiofuranyl, benzisoxazolyl, benzoxazolyl, benzodioxolyl, furanopyridinyl, purinyl, imidazopyridinyl, imidazopyrimidinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, thienopyridinyl, triazolopyrimidinyl, triazolopyridinyl, anthranilyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, oxochromanyl, and 1,4-benzoxazinyl, each of which is optionally substituted with one to three R^9.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is a (C_6-C_{10})aryl and the aryl is phenyl optionally substituted with one to three R^9 independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_1-C_6)alkoxy, -$N(R^5)(R^6)$, -$(SO_2)R^7$, and -$S(=O_2)N(R^5)(R^6)$, wherein R^5 and R^6 at each occurrence are each independently selected from the group consisting of hydrogen and (C_1-C_6)alkyl, and R^7 is a (C_1-C_6)alkyl.

8. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is a (5- to 14-membered)heteroaryl and the heteroaryl is selected from the group consisting of oxazolyl, pyrazolyl, thiophenyl, thiazolyl, triazolyl, pyridinyl, pyrimidinyl triazolopyridinyl and furopyridinyl, each of which is optionally substituted with one to three R^9 independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, optionally substituted (C_1-C_6)alkyl, optionally substituted (C_1-C_6)alkoxy, -$N(R^5)(R^6)$, -$(SO_2)R^7$, and -$S(=O_2)N(R^5)(R^6)$, wherein R^5 and R^6 at each occurrence are

each independently selected from the group consisting of hydrogen and (C_1-C_6)alkyl, and R^7 is a (C_1-C_6)alkyl.

9. The compound according to any one of claims 6-8, or a pharmaceutically acceptable salt thereof, wherein each R^9 is independently selected from the group consisting of fluoro, chloro, cyano, (C_1-C_6)alkyl and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6).

10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R^9 is selected from:

i) a (C_1-C_6)alkyl selected from the group consisting of methyl, ethyl and propyl, and the methyl, ethyl and propyl are optionally substituted with one to three fluorine atoms; and

ii) a (C_1-C_6)alkoxy selected from the group consisting of methoxy, ethoxy or propoxy and the methoxy, ethoxy and propoxy are optionally substituted with one to three fluorine atoms.

11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (4- to 6-membered)heterocycloalkyl and (5- to 6-membered)heteroaryl, wherein the (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, (4- to 6-membered)heterocycloalkyl and (5- to 6-membered)heteroaryl are optionally substituted with one to three R^8 independently selected from the group consisting of halogen, cyano, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6), provided that when ring A is a fused phenyl ring, R^2 is not a (C_1-C_6)alkyl substituted with N(R^5)(R^6).

12. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen.

13. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is a (C_1-C_6)alkyl selected from the group consisting of methyl, ethyl, and propyl, each of which is optionally substituted with one to three R^8 independently selected from the group consisting of halogen, cyano, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6), provided that when ring A is a fused phenyl ring, R^2 is not a (C_1-C_6)alkyl substituted with N(R^5)(R^6).

14. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is a (C_3-C_8)cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl each of which is optionally substituted with one to three R^8 independently selected from the group consisting of halogen, cyano, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6).

15. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R^2 is cyclopropyl.

16. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is a (5- to 6-membered)heteroaryl and the heteroaryl is selected from the group consisting of oxazolyl, pyrazolyl, thiophenyl, thiazolyl, triazolyl, pyridinyl, and pyrimidinyl, each of which is optionally substituted with one to three R^8 independently selected from the group consisting of halogen, cyano, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy, wherein the alkyl and alkoxy are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6).

17. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^{3a}, where chemically permissible, is selected from the group consisting of hydrogen, halogen, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, and (C_3-C_8)cycloalkyl; R^{4a}, where chemically permissible, is selected from the group consisting of hydrogen, halogen, (C_1-C_6)alkyl and (C_3-C_8)cycloalkyl; and wherein the alkyl, alkoxy and cycloalkyl are each optionally substituted with one to three substituents selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF_5, nitro, -C(=O)-R^5 and -N(R^5)(R^6).

18. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^{3a} taken together with the nitrogen and carbon atoms to which they are attached form a (4- to 6-membered)heterocycloalkyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, and morpholinyl, each of which is optionally substituted with one to three R^8.

19. The compound according to any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R^{3b}, where chemically permissible, is selected from the group consisting of hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, and (C_3-C_8)cycloalkyl; R^{4b}, where chemically permissible, is selected from the group consisting of hydrogen, halogen, oxo, cyano, hydroxy, -SF_5, nitro, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy; and wherein the (C_1-C_6)alkyl, (C_1-C_6)alkoxy, and (C_3-C_8)cycloalkyl are optionally substituted with one to three R^8.

20. A compound selected from the group consisting of:

10-(4-Chlorophenyl)-8-cyclopropyl-7,8-dihydropyrido[2’,3’:4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

8-Cyclopropyl-10-(3-fluoro-4-methoxyphenyl)-7,8-dihydropyrido[2’,3’:4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

4-(11-Oxo-6a,7,8,9-tetrahydro-6*H*,11*H*-pyrido[2’,3’:4,5]pyrrolo[1,2-*a*]pyrrolo[1,2-*d*]pyrazin-12-yl)benzonitrile;

10-(4-Chloro-2-fluorophenyl)-8-cyclopropyl-7,8-dihydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

4-(7-Cyclopropyl-8-oxo-5,6,7,8-tetrahydro[1,3]thiazolo[4',5':4,5]pyrrolo[1,2-*a*]pyrazin-9-yl)-3-methylbenzonitrile;

(6a*S*)-12-(4-Chlorophenyl)-6a,7,8,9-tetrahydro-6*H*,11*H*-pyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrrolo[1,2-*d*]pyrazin-11-one;

10-(4-Chlorophenyl)-7,8-dihydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

4-(8-Cyclopropyl-9-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-10-yl)-3-fluorobenzonitrile;

8-Cyclopropyl-10-(4-fluoro-2-methylphenyl)-7,8 dihydropyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

8-Cyclopropyl-10-(6-methoxypyridin-3-yl)-7,8-dihydropyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

(7*S*)-10-(4-Chlorophenyl)-8-cyclopropyl-7-methyl-7,8-dihydropyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one;

4-(8-Cyclopropyl-9-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-10-yl)-3-methylbenzonitrile;

5-(8-Cyclopropyl-9-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-10-yl)pyridine-2-carbonitrile;

10-(4-Chloro-2-methylphenyl)-8-cyclopropyl-7,8-dihydropyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one; and

4-(7-Cyclopropyl-8-oxo-5,6,7,8-tetrahydro[1,3]thiazolo[4',5':4,5]pyrrolo[1,2-*a*]pyrazin-9-yl)-2-fluoro-5-methylbenzonitrile;

or a pharmaceutically acceptable salt thereof.

21. A compound, wherein the compound is 4-(7-Cyclopropyl-8-oxo-5,6,7,8-tetrahydro[1,3]thiazolo[4',5':4,5]pyrrolo[1,2-*a*]pyrazin-9-yl)-2-fluoro-5-methylbenzonitrile, or a pharmaceutically acceptable salt thereof.

22. A compound, wherein the compound is 8-Cyclopropyl-10-(3-fluoro-4-methoxyphenyl)-7,8-dihydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one, or a pharmaceutically acceptable salt thereof.

23. A compound, wherein the compound is 10-(4-Chloro-2-fluorophenyl)-8-cyclopropyl-7,8-dihydropyrido[2',3':4,5]pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one, or a pharmaceutically acceptable salt thereof.

24. A compound, wherein the compound is 10-(4-Chloro-2-methylphenyl)-8-cyclopropyl-7,8-dihydropyrido[2',3':4,5] pyrrolo[1,2-*a*]pyrazin-9(6*H*)-one, or a pharmaceutically acceptable salt thereof.

25. Use of a compound as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition mediated by the PDE4B isoform, wherein said disease or condition is selected from the group consisting of schizophrenia, depression, anxiety, Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammation, stroke, asthma, cerebral vascular disease, allergic conjunctivitis, psychosis, psoriatic arthritis, traumatic brain injury, epilepsy, autoimmune and inflammatory diseases, and behavioral disorders due to drug dependence and abuse.

26. The compound as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or condition mediated by the PDE4B isoform, wherein said disease or condition is selected from the group consisting of schizophrenia, depression, anxiety, Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammation, stroke, asthma, cerebral vascular disease, allergic conjunctivitis, psychosis, psoriatic arthritis, traumatic brain injury, epilepsy, autoimmune and inflammatory diseases, and behavioral disorders due to drug dependence and abuse.

27. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

28. Use of a pharmaceutical composition as defined in claim 27 in the manufacture of

a medicament for the treatment of a disease or condition mediated by the PDE4B isoform, wherein said disease or condition is selected from the group consisting of schizophrenia, depression, anxiety, Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammation, stroke, asthma, cerebral vascular disease, allergic conjunctivitis, psychosis, psoriatic arthritis, traumatic brain injury, epilepsy, autoimmune and inflammatory diseases, and behavioral disorders due to drug dependence and abuse.

29. The pharmaceutical composition as defined in claim 27 for use in the treatment of a disease or condition mediated by the PDE4B isoform, wherein said disease or condition is selected from the group consisting of schizophrenia, depression, anxiety, Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammation, stroke, asthma, cerebral vascular disease, allergic conjunctivitis, psychosis, psoriatic arthritis, traumatic brain injury, epilepsy, autoimmune and inflammatory diseases, and behavioral disorders due to drug dependence and abuse.